KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial.

Lori L Davis, Saloni Behl, Daniel Lee, Hui Zeng, Taisa Skubiak, Shelley Weaver, Nanco Hefting, Klaus Groes Larsen, Mary Hobart

J Clin Psychopharmacol 45(6) 580-589

PMID40982703
PMCIDPMC12573675
DOI10.1097/JCP.0000000000002076
发表日期2025-09-22
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。
摘要

摘要

PURPOSE: This trial aimed to investigate the efficacy, safety, and tolerability of fixed-dose brexpiprazole in combination with sertraline for posttraumatic stress disorder (PTSD). METHODS: This was a phase 3, randomized, parallel-arm trial in adult outpatients with PTSD, across 95 sites in the United States (ClinicalTrials.gov: NCT04174170). After a 1-week placebo run-in, participants entered 11 weeks of randomized (1:1:1) double-blind treatment with brexpiprazole 2 mg/d+sertraline 150 mg/d, brexpiprazole 3 mg/d+sertraline 150 mg/d, or sertraline 150 mg/d+placebo (active control). The primary endpoint was the change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score from randomization (week 1) to week 10. Safety was also assessed. FINDINGS: The trial (October 2019 to August 2023) screened 1821 participants, and randomized 553 (brexpiprazole 2 mg+sertraline, n=191; brexpiprazole 3 mg+sertraline, n=185; and sertraline+placebo, n=177). All groups showed CAPS-5 total score reductions [LS mean (SE) change at week 10: brexpiprazole 2 mg+sertraline, -16.5 (1.2), n=132; brexpiprazole 3 mg+sertraline, -18.3 (1.2), n=124; and sertraline+placebo, -17.6 (1.2), n=130]. LS mean differences (95% CI) versus sertraline+placebo at week 10: brexpiprazole 2 mg+sertraline, 1.03 (-2.09 to 4.16), P =0.52; brexpiprazole 3 mg+sertraline, -0.71 (-3.88 to 2.46), P =0.66. Treatment-emergent adverse events with incidence ≥5% for either brexpiprazole+sertraline group were headache (brexpiprazole 2 mg+sertraline, 7.0%; brexpiprazole 3 mg+sertraline, 5.6%; and sertraline+placebo, 7.6%), nausea (4.9%; 8.3%; 8.7%), and diarrhea (3.8%; 6.1%; 6.4%). CONCLUSIONS: PTSD symptom improvement was similar with fixed-dose brexpiprazole+sertraline and sertraline+placebo; the primary endpoint was not met. This differs from 2 prior trials that showed greater efficacy for brexpiprazole+sertraline versus sertraline+placebo. No new safety signals were observed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Participant disposition. CAPS-5, Clinician-Administered PTSD Scale for DSM-5. a Aggregated reasons for discontinuation were as follows: (1) withdrawal by participant + lost to follow-up + adverse event: 26.2% (50/191) for brexpiprazole 2 mg + sertraline, 26.5% (49/185) for brexpiprazole 3 mg + sertraline, and 26.6% (47/177) for sertraline + placebo; (2) lost to follow-up + adverse event: 16.2% (31/191) for brexpiprazole 2 mg + sertraline, 10.8% (20/185) for brexpiprazole 3 mg + sertraline, and 18.6% (33/177) for sertraline + placebo. b The efficacy sample was enriched for participants who had a CAPS-5 total score ≥27 at the randomization visit (week 1) and who had <50% improvement in CAPS-5 total score from baseline (day 0) to week 1.
非 KM Figure
FIGURE 2FIGURE 2 Mean change in CAPS-5 total score (primary endpoint). CAPS-5, Clinician-Administered PTSD Scale for DSM-5; LS, least squares; MMRM, mixed model for repeated measures. All comparisons had P >0.05 versus sertraline + placebo; MMRM, efficacy sample. Mean CAPS-5 total score at randomization (Week 1): brexpiprazole 2 mg + sertraline, 38.8; brexpiprazole 3 mg + sertraline, 37.9; sertraline + placebo, 39.3.
非 KM Figure